No. of Recommendations: 0
re: Lilly vs Novo Nordisk
me, a month ago, moaning re NVO fumbling the ball badly in the preceding 12 months:(
sutton replies on I'm thinking this is the third time )
Plan for now:
- no changes. I think LLY continues to execute, and NVO is at least talking the talk with their new CEO (and oral med): "The chief executive appointed to stop the rot says Novo failed to get to grips with the changing dynamics of the market, notably the US" WSJ today:
"
In the week ended July 3, Novo Nordisk’s Wegovy pill generated about 153,050 U.S. prescriptions compared with 19,550 for Eli Lilly’s Foundayo pill...Adjusting for its few months’ head start this year, Novo Nordisk is still outpacing Lilly. Its Wegovy pill had around 105,000 prescriptions during its 13th week on sale, more than five times Foundayo’s, according to Jefferies analysts who called Lilly’s launch “muted.”--sutton
too hot/smoky outside to do, you know, worthwhile things
